Background: MLN4924 is an investigational first-in-class small molecule inhibitor of NEDD8-activating enzyme (NAE). NAE is an essential component of the NEDD8 conjugation pathway, controlling the activity of a subset of ubiquitin-proteasome system (UPS) E3 ligases, multiprotein complexes that transfer ubiquitin molecules to substrate proteins. Procedures: MLN4924 was tested against the PPTP in vitro panel using 96-hour exposure time at concentrations ranging from 1.0nM to 10μM. It was tested in vivo at a dose of 100mg/kg [66mg/kg for the acute lymphoblastic leukemia (ALL) xenografts] administered orally twice daily×5 days. Treatment duration was 3 weeks. Results: The median relative IC 50 for MLN4924 against the PPTP cell lines was 143nM, (range: 15-678nM) with that for the Ewing panel being significantly lower (31nM). MLN4924 induced significant differences in EFS distribution compared to control in 20 of 34 (59%) evaluable solid tumor xenografts. MLN4924 induced intermediate activity (EFS T/C values >2) in 9 of the 33 evaluable xenografts (27%), including 4 of 4 glioblastoma xenografts, 2 of 3 Wilm's tumor xenografts, 2 of 5 rhabdomyosarcoma xenografts, and 1 of 4 neuroblastoma xenografts. For the ALL panel, 5 of 8 evaluable xenografts showed intermediate activity for the EFS T/C measure. MLN4924 did not induce objective responses in the PPTP solid tumor or ALL panels. Conclusions: MLN4924 showed potent activity in vitro and in vivo showed tumor growth inhibitory activity against a subset of the PPTP solid tumor and ALL xenografts.
|Number of pages||8|
|Journal||Pediatric Blood and Cancer|
|State||Published - Aug 2012|
- Developmental therapeutics
- Preclinical testing
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health